Compare · DYN vs NVO
DYN vs NVO
Side-by-side comparison of Dyne Therapeutics Inc. (DYN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DYN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 65.4x DYN ($2.92B).
- DYN has been more active in the news (16 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 20 for DYN).
- Company
- Dyne Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $2.92B
- $191.15B
- 1M return
- -3.86%
- -
- 1Y return
- +20.96%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 16
- 8
- Recent ratings
- 20
- 25
Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DYN
- SEC Form 4 filed by Director Hurwitz Edward
- SEC Form 4 filed by Director Lubner David Charles
- SEC Form 4 filed by Director Rhodes Jason P
- SEC Form 4 filed by Director Kersten Dirk
- SEC Form 4 filed by Director Incerti Carlo
- SEC Form 4 filed by Director Stehman-Breen Catherine
- Director Posner Brian S bought $33,880 worth of shares (2,000 units at $16.94), increasing direct ownership by 9% to 24,500 units (SEC Form 4)
- Dyne Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Posner Brian S bought $43,700 worth of shares (2,500 units at $17.48), increasing direct ownership by 12% to 22,500 units (SEC Form 4)
- Dyne Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care